

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Lidocaine hydrochloride/adrenaline

(excluding preparations for dental use)

December 21, 2020

Therapeutic category

Local anesthetics

Non-proprietary name

Lidocaine hydrochloride/adrenaline

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions):

Revised language is underlined.

Current	Revision
<p>Contraindications [Conduction anaesthesia/infiltration anaesthesia] Patients for whom anaesthesia is intended for <u>ears, digits, or penis</u></p> <p>Careful Administration (N/A)</p>	<p>Contraindications [Conduction anaesthesia/infiltration anaesthesia] Patients for whom anaesthesia is intended for penis</p> <p>Careful Administration <u>[Conduction anaesthesia, infiltration anaesthesia (to ears or digits)]</u> <u>Patients with systemic or peripheral blood flow disorder, patients who are to receive simultaneous injections to multiple digits, and pediatric patients. (A necrotic condition may occur. Appropriateness of administration of this drug should be considered carefully. If administration is decided upon, measures such as reducing the dose of this drug should be taken as appropriate.)</u></p>

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
 E-mail: safety.info@pmda.go.jp